Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Conference on Recombinant AntibodiesConference to be held at 22nd - 23rd January 2009, BSG Conference Centre, London, UK
By: bharatbook.com To be held at 22nd - 23rd January 2009, BSG Conference Centre, London, UK Key Speakers Dr Matthew Baker, Chief Scientific Officer, Antitope Dr David Blakey, Chief Scientist, Oncology, AstraZeneca / MedImmune Dr Michael Kragh, Director of Antibody Pharmacology, Symphogen Dr. Christian Klein, Department Head Discovery Oncology, Pharma Research, Roche Diagnostics Dr Rathin C. Das, President, Affitech USA, Senior VP Corp Development & CBO, Affi tech Group Dr Frederic Fellouse, Samuel Lunenfeld Research Institute, Mount Sinai Hospital Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics Dr René Hoet, Sr. Director, Research, Genmab Dr Candi Soames, Partner, Edwards Angell Palmer & Dodge Dr David R. Buckler, Director of Research Alliances, Dyax Philippe Stas, CEO, Algonomics, President, European Immunogenicity Platform Dr Michael Steward, Manager, Biopharm CEDD Domantis Professor Serge Muyldermans, VIB Department of Molecular and Cellular Interactions, Vrije Universiteit Brussel Dr Ulrich Rothbauer, BioCenter, Department of Biology, Ludwig Maximilians University Dr Philip Webber, European Patent Attorney, Frank B Dehn Dr Hilde Revets, Director Cell Biology and Immunology, Ablynx Dear Colleague, The protein therapeutics market remains one of the fastest growing segments of the pharma market, and recombinant antibodies have gained enormous importance for clinical applications. Visiongain’s greatly anticipated event will enable you to examine these current applications, and latest developments in the fi eld of antibody engineering. Recombinant antibodies have distinct advantages compared with conventional antibodies such as, rapid growth and ease of manipulation, making them the ideal choice for expression of non-glycosylated peptides and proteins. Innovative product classes such as alternative binding molecules will further expand their use, whilst novel engineered production hosts and integrated technology platforms hold huge potential for future applications. By attending Visiongain’s 2nd Annual Recombinant Antibodies Conference you will gain a comprehensive outlook for the protein therapeutics market from product development to strategic issues and market trends. Reasons to register today: • Hear from key researchers and decision makers in the field of antibody engineering • Examine the current market environment for therapeutic antibodies and assess market potential • Discover recent developments in antibody display and selection techniques • Understand the regulatory requirements for recombinant therapeutic antibodies and hear strategies for protecting antibodies • Learn practical measures for predicting and minimising immunogenicity • Identify potential protein therapeutics areas for partnerships and collaboration • Be part of a unique networking opportunity I look forward to meeting you at the conference. Best regards Andrea Charles Head of Conferences Who should attend: VPs, Directors, Heads and Managers of: • Research & Development • Protein Engineering • Antibody Engineering • Preclinical Development • Clinical Development • Antibody Development • Immunology (Research) • Immunogenicity • (Clinical) Oncology • Oncology Research • Oncology Discovery • IP/ Patents • New Product Development • Business Development • Marketing • Licensing For more information kindly visit: http://www.bharatbook.com/ OR Contact us at Bharat Book Bureau 207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India. Phone : +91 22 2757 8668 / 2757 9438 Fax : +91 22 2757 9131 E-mail : info@bharatbook.com Website : www.bharatbook.com End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number